NOVEL PDOX DRUG DEVELOPMENT

A selection of novel drugs that have been developed via the PDOX process. For more information and references, please contact us.

  • The metalioproteinase inhibitor Batimastat:  Active against a SOI human-patient colon tumor model including:
    • Inhibition of primary tumor growth
    • Inhibition of metastatic events
    • Extension of survival
  • The metalioproteinase inhibitor CT1746:  Active against a SOI human colon tumor xenograft model:
    • Arrest of primary tumor growth
    • Inhibition of metastatic events, and
    • A large increase in survival
  • IFN-y:  Active against a patient pleural cancer SOI Model:
    • Elimination of metastatic events
    • Decrease in cachexia, and
    • Extension of survival
  • Angiogenesis inhibitor TNP-470:  Active in patient colon and stomach tumor SOI models:
    • Inhibition of liver metastasis in colon cancer
    • Minimal or no effect on tumor
  • Anti-VEGF antibody:  Active in SOI model of colon and stomach cancer:
    • Inhibition of liver metastasis in colon cancer
    • Minimal or no effect on primary tumor
  • Antisense phosporothionate oligionucleotide specific for VEGF-receptor active in SOI model of stomach cancer:
    • Inhibition of peritoneal tumor dissemination
    • Increased tumor cell apoptosis
    • Microvessel density (MVD) in tumor nodules
  • New platinum analogs {Pt(cis-dach)(DPPE)-2NO3} and {Pt(trans-dach)(DPPE)-2NO3) active in SOI model of bladder and stomach cancer:
    • No metastasis in either of the high- or low-dose platinum-analog-treated groups in SOI model of bladder cancer.
    • No mesenteric lymph node metastasis in the groups treated with the high or low doses of both new platinum analogs with SOI model of colon cancer
  • Liposomal doxorubicin (Doxil):
    • Inhibition of MDA-MB-231 human breast tumor xenografts, which were resistant to free doxorubicin
  • Camptothecin analog DX-8951f:  Active in SOI models of pancreatic cancer:
    • DX-8915f showed efficacy against two human pancreatic tumor cell lines in SOI-GFP model, DX-8915f was highly effective against the primary and metastatic growth in the two models and showed significantly higher efficacy than gemcitabine, the standard treatment of pancreatic cancer.
  • Cytosine analog, CS-682:  Active in the SOI model of pancreatic cancer:
    • CS-682 showed efficacy on inhibiting pancreatic cancer growth and metastasis in RFP orthotopic nude mouse model of human pancreatic model.
    • CS-682 showed efficacy in an adjuvant treatment orthotopic model of human pancreatic cancer suggesting possibility of chronic use of CS-682 to control pancreatic cancer.
  • Estrogen analog 2-methoxyoestradiol-bis-sulphamate:  Active in MDA-MB-435 SOI model of breast cancer
  • Truncated galectin-3 (galectin-3C) was found active in orthotopic breast cancer xenograft nude mouse model imaged with green fluorescent protein
  • The agonistic anti-LTBR monoclonal antibody (mAb) CBE11 inhibited tumor growth in xenograft models and potentiated tumor responses to chemotherapeutic agents
  • Additive effects of glufosfamide and gemcitabine in fluorescent orthotopic mouse models of human pancreatic cancer
  • A monoclonal antibody to the chemokine receptor CXCR2 was effective against pancreatic cancer in the SOI model
  • TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche
  • Type II PDGFRB/B-RAF inhibitor disrupts angiogenesis and tumor growth
  • A small molecule inhibitor of SDF-1/CXCR4 inhibits vasculogenesis, but not angiogenesis, and prevents the recurrence of glioblastoma following irradiation in mice
  • HER-2 therapy inhibits metastasis of esophageal cancer
  • Metronomic gemcitabine therapy greatly inhibits metastasis of pancreatic cancer
  • Bisphosphonate olpadronate inhibits bone metastasis in prostate cancer
  • Knockdown of the B1 integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis
  • High antimetastatic efficacy of MEN4901/T-0128, a novel camptothecin carboxymethyldextran conjugate
  • Imaging the inhibition by anti-B1 integrin antibody on lung seeding of single cells in live mice
  • Efficacy of the Chinese traditional medicinal herb Celastrus orbiculatus Thunb on human hepatocellular carcinoma in an orthotopic fluorescent nude mouse model
  • Real-time imaging of induction of apoptosis of human breast cancer cells by the traditional Chinese medicine herb Tubeimu

Feasibility for the drug discovery in the SOI models has been demonstrated with colon, pancreatic, stomach, bladder, and lung cancer where chemotherapy has resulted in dose-response, differential sensitivity of primary and metastatic tumors, reproducibility, and correlation to historical clinical activity of the drugs including 5-FU, CDDP, mitomycin-C, as well as new agents listed above.

To learn more about AC PDOX’s novel drug development, please contact us at info@anticancerpdox.com.